Adversarial review. C1 major_issues; C2 major_issues; C3 major_issues; C4 major_issues; C5 major_issues; C6 sound; C7 major_issues; C8 major_issues.

All seven result JSON files reproduce exactly in an isolated Python3.12 environment with NumPy2.1.3/SciPy1.14.1, an alternate environment to the declared2.5.3/1.18.1. Code ran in2.76seconds, no network or host mounts. All334 downloaded files passed supplied SHA256 and size checks. I read the paper, claims, counting/statistical/summarization code and examined raw structured event counts with reviewer-written audit code. I did not independently manually rescreen539 studies or recode4644 terms. No publisher identity was sought or learned. This report challenges interpretation/measurement, not the reproducibility of arithmetic.

1. Composite counts are not participant risks (C1-C5,C7-C8; organ-system component of C3). The paper helpfully discloses summing per-term numAffected, but then calls these participants affected and applies binomial risk-ratio formulas. Cross-term overlap can differ between arms, altering point estimates, not just variances. Neither capped sums, random effects, splitting trials, nor leave-one-out fixes that. Counting repeated term-person memberships is not the same as counting clinical events either. The supplied code's inflate argument leaves the point estimate unchanged.

I independently extracted per-original-event-group union bounds, keeping the author's term classification. Lower=max(largest included term count, overall seriousNumAffected minus sum of excluded term counts); upper=min(sum included term counts,overall seriousNumAffected). Bounds are added across separate groups. No repeated event-group IDs across included comparisons and no missing overall seriousNumAffected totals were found. Conditional on the submitted records and coding, drug/placebo union ranges are bacterial infection458-2409/430-2532; pneumonia880-1442/970-1568; gallbladder418-967/237-589; nausea-vomiting136-200/54-83; pancreatitis171-229/119-173; obstruction82-171/70-153; thyroid59-67/26-32; malignant neoplasm371-2379/295-2141; obesity-associated cancer209-973/143-808; pancreatic cancer62-103/56-95. These wide identification bounds are not claims of plausible biological configurations, confidence intervals, or evidence of the opposite clinical effect. They show that aggregates alone do not identify unique-person risks.

For example the MH point estimates range0.154-4.999 for bacterial infection and0.523-1.394 for pneumonia over the allowed extreme overlap configurations. Strong unadjusted signals in the original summed counts therefore do not constitute a mathematically overlap-robust risk reduction. The paper's single-preferred-term pneumonia analysis is useful evidence that should be distinguished from the unidentified composite. A defensible revision should use verified unique-person outcomes or report sensitivity to arm-specific overlap and an explicit term-membership estimand with suitable uncertainty. Do not silently reinterpret the audit extremes as estimated risks.

The so-called conservative bound also lacks its claimed guarantee. overlap_bound() caps an outcome-specific count ratio by the all-SAE overcount factor. Counterexample:100 participants have an SAE; one has three distinct infection terms and the other99 each one non-infection term. The overall factor is102/100=1.02; the infection sum/union factor is3/1=3. The global average is not an upper bound for a particular outcome. Further, even a valid count-overstatement bound is not automatically a valid variance multiplier for a ratio under arbitrary within-person and arm-specific dependence. Derive the guarantee or label this a heuristic sensitivity, not conservative assurance.

2. The atlas comparison does not compare like estimands (C4,C5). The code's va_category(e,hr,lo,hi) accepts the atlas interval but never uses lo or hi; it compares only the point HR to the trial CI. This is a literal interval-to-number comparison, not a test of disagreement between two uncertain estimates. It also contrasts serious-event-only risk over heterogeneous follow-up with incident diagnoses/time-to-event in a usual-care observational population. The Discussion acknowledges this, but 'confirm/exclude' tallies and the abstract remain too strong. Call them operational concordance categories. An infection estimate near the atlas value does not establish that the cohort association was not mainly confounded; distinct biases and different estimands can coincide.

The most direct substantive counterexample to the pancreatitis comparison is subtype versus aggregate. An increased drug-induced subtype can coexist with unchanged all-cause pancreatitis if other causes fall. For example equal baseline risks of a drug-attributed subtype and another cause, changed by factors2.46 and0.50, give total RR1.48; with a smaller subtype share total RR can be even closer to1. No contradiction follows. Recent primary evidence addresses this exact distinction: Xie et al.2026, GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: target trial emulation, https://doi.org/10.1136/bmjmed-2025-002183 (https://pmc.ncbi.nlm.nih.gov/articles/PMC13110570/), reports increased suspected drug-induced pancreatitis alongside decreased hypertriglyceridaemia-associated and alcohol-induced pancreatitis. This is observational evidence, not a causal resolution, but it makes the omitted subtype issue concrete. The atlas itself is https://www.nature.com/articles/s41591-024-03412-w and explicitly concerns drug-induced pancreatitis. The current study cannot exclude that subtype's HR from a total-pancreatitis RR interval.

3. Non-significance is not evidence of no increase (C7,C8). Obstruction RR1.03 is above1, with interval0.82-1.28. Thus 'is not more frequent' is not established even using the original count model; it permits a28% increase and has no stated equivalence margin. The neuropathy estimate is correctly called uncertain (0.51-5.14). Cancer results should say 'no statistically significant difference after correction', not no difference/no increased risk, and distinguish limited follow-up from lifetime carcinogenic risk. The union uncertainty applies to cancer composites too.

Per-claim disposition and required changes:
C1 major_issues: trial/comparison counts reproduce and observed controls agree with expectations, but the composite RR is not an identified unique-person risk; restrict the estimand and repair counting. A positive control cannot validate unrelated composites.
C2 major_issues: strongest objection is differential within-person overlap and an unproved variance guarantee, not failure of the code to reproduce. Preserve the individual-term pneumonia result and prior evidence, but do not make a new treatment recommendation from these aggregate composite risks.
C3 major_issues: the reported discovery/replication list reproduces. Four organ-system composites inherit counting defects. The two preferred-term findings are less affected, subject to checking synonymous duplicate rows. The second half is an internal held-out split, not independent external replication; the candidate event filter and overlap calibration use both halves, which should be disclosed rather than implying a wholly untouched second sample. Discovery BH plus unadjusted replication p<0.05 is the registered selection rule, not by itself proof of family-wide controlled replicability error. No claim here that the specific two preferred-term signals are false.
C4 major_issues: category totals are reproduced but inherit counting, non-comparable estimands and point-only comparisons. '80% power' is a simplified count-based approximation for an unadjusted5% test, not power for the actual BH procedure, heterogeneous trials or the clinical atlas estimand. Counts may include repeated people. Keep the careful inconclusive classification of sparse neuropsychiatric outcomes.
C5 major_issues: reported229/173 are term-membership sums with union ranges above. Independently of that, all-cause versus drug-induced comparison cannot refute a2.46-fold subtype hazard. The literal numerical inequality is not the scientific conclusion advertised.
C6 sound within the stated registry sample: deaths and any-SAE use group union totals, not term sums. Source totals are present; death subset denominators are correctly stated. All numerical and registered sensitivity outputs reproduce. No serious-event missing-total coercion was found. This does not ensure equal follow-up or generalize beyond the included trials, but those limitations do not defeat the narrow reported comparison.
C7 major_issues: restrict to failure to reject under the registered procedure, repair composite numerators, and do not use these as negative controls to dismiss differential observation without an equivalence analysis.
C8 major_issues: replace 'not more frequent' by 'no statistically detectable increase under this analysis'; report compatible harm and composite ambiguity. Retain the neuropathy uncertainty.

Significance: C1 minor (corpus/control), C2 moderate (a useful registry confirmation if measurement is repaired), C3 moderate (systematic held-out screening), C4 moderate (potentially useful atlas-to-trial comparison if aligned), C5 minor (current non-comparable numerical contrast), C6 moderate (registry confirmation of important safety/mortality outcomes), C7 minor and C8 minor (limited nulls). These are confirmation values, not novelty claims. Han et al.2025, https://www.journalofinfection.com/article/S0163-4453%2825%2900245-2/fulltext , already reports136RCTs and lower serious infection risk (RR0.89,0.86-0.93); the current paper appropriately cites it and should not imply an independent new clinical discovery. Source interpretation for unique affected participants versus term counts follows ClinicalTrials.gov definitions, https://clinicaltrials.gov/policy/results-definitions . Findings here warrant measurement/wording corrections, not prescribing advice or claims that infection benefits are disproved.